Strategy

Jun 01, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches.
Jun 01, 2007
Pharmaceutical Executive
To harness consumerization to improve the industry's image and enhance the value of its products, pharma leaders need to focus on the "Four Cs": commitment, choice, collaboration, and customization
May 23, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Beneficiaries don't switch back to brands after trying generics.
May 01, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Today's highest science, most fierce competition—and make no mistake, biggest gains—are coming from the oncology arena. In fact, there are more than 380 cancer compounds in development, according to a recent report by IMS Health, with almost 100 of them in Phase III trials.
Apr 25, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Drug industry leads in 'world class' competitive intelligence.
Apr 18, 2007
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Biotech restructures to become a bigger force in the cancer market.
Apr 01, 2007
Pharmaceutical Executive
Ever wonder how all those biotechs, specialty shops, and generics that make up Not Big Pharma ever manage to stay in business? Pharm Exec asked Bill Trombetta of St. Joseph's University to look at their books, analyzing their financial performance with the same metrics he uses for our annual Industry Audit. His findings may surprise you. In fact, when you check the bottom line, you just might consider changing teams.
Apr 01, 2007
Pharmaceutical Executive
Everyone agrees that by streamlining and downsizing, Big Pharma is taking a step in the right direction. What no one yet knows is if it's too little, too late. Or what "too little, too late" might look like. Or what else might work.
Apr 01, 2007
Pharmaceutical Executive
Dr. Doug Bierer felt like he was in a courtroom, waiting for the jury to render its verdict. It was June 2002, and executives from Procter & Gamble and its partner AstraZeneca had just finished presenting their bid to FDA's Non-Prescription Drugs Advisory Committee (NDAC) to market the popular heartburn medication, Prilosec (omeprazole), as an over-the-counter (OTC) drug.
Apr 01, 2007
Pharmaceutical Executive
And while reporters aren't writing any more about the industry, the topics they cover are a moving target.
native1_300x100
lorem ipsum